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TABLE 1 Patient Proﬁles
Patient #1 Patient #2 Patient #3
Age, yrs 68 75 87
Sex Female Male Male
Pre-TMVR NYHA functional class IV IV III
Glomerular ﬁltration rate, ml/min 47 18 44
Previous CABG Yes Yes No
Heart failure hospital admission
in previous 6 months
2 1 1
Etiology MR Secondary Primary Primary
Pre-TMVR MR grade (EROA, cm2) 0.34 0.79 1.39
Post-TMVR MR grade None Trivial None
Post-TMVR peak/mean mitral
gradient, mm Hg
8/3 11/5 7/2
Length of hospital stay, days 20 7 5
Discharge destination Home Home Home
CABG ¼ coronary artery bypass grafting; EROA ¼ effective regurgitant oriﬁce area;
MR ¼ mitral regurgitation; NHYA ¼ New York Heart Association; TMVR ¼ trans-
mitral valve replacement.
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2353activities of daily living, with the last patient being
discharged on the ﬁfth post-operative day. All have
reported a marked symptomatic improvement.
The complex pathoanatomy of the mitral valve will
present a difﬁcult challenge for TMVR compared with
TAVR. All the devices with early clinical experience
have their advantages and disadvantages, and much
work remains to be done before TMVR becomes a
viable therapeutic alternative to surgical valve repair/
replacement. However, the FIH experience with this
system is a promising beginning. Stabilization by
means of an apical tether is a novel way to attempt to
minimize the risk of device migration, left ventricular
outﬂow tract obstruction, and paravalvular leakage.
The unique design features of this device also offer
the potential for it to be useful across a wide range of
mitral valve pathologies.*Neil Moat
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in College AthletesSudden cardiac death (SCD) is the leading cause
of death in college athletes during sports (1). Pre-
participation examinations are required in college
athletes, although the best screening protocol to
identify cardiovascular diseases known to cause SCD
is debated. The purpose of this study was to
examine results from a single National Collegiate
Athletic Association (NCAA) Division I institution
with extensive experience conducting electrocar-
diograms (ECGs) in the cardiovascular screening of
athletes.
Routine 12-lead ECG screening of all intercollegiate
athletes undergoing pre-participation evaluations
at the University of Washington began in August
2010. The screening evaluation included a standard-
ized history questionnaire from the Pre-Participation
Physical Evaluation Monograph (4th edition), phys-
ical examination, and resting ECG. ECG interpretation
was guided by modern standards, and screening
abnormalities underwent additional evaluation in
consultation with cardiovascular specialists.
Findings were compared among student athletes
using the Fisher exact test, and statistical signiﬁcance
was deﬁned as p < 0.05. The primary outcome mea-
sure was the identiﬁcation of disorders associated
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versity of Washington approved the study.
Data from 790 consecutive athletes screened be-
tween August 2010 and June 2014 were analyzed. Of
the athletes, 56.2% were male, the mean age was 18
years (range, 17 to 25 years), 59.4% were Caucasian,
14.6% were African-American, 3% were Asian, 23.2%
were of other/mixed race, and they participated in 19
different intercollegiate sports plus cheerleading.
At least 1 positive cardiovascular symptom or
family history response was reported by 294 athletes
(37.2%). Female athletes were more likely to report at
least 1 positive symptom or family history response
(43.3%) versus male athletes (32.4%) (p ¼ 0.002).
The most common history responses were syncope/
near-syncope during or after exercise (7.4%), chest
discomfort/pain/tightness/pressure during exercise
(5.1%), and a family history of a heart problem, a
pacemaker, or an implanted deﬁbrillator (15.2%).
Physical examination ﬁndings were abnormal in 28
athletes (3.5%), including 26 athletes (3.3%) with a
heart murmur and 2 athletes (0.3%) with physical
stigmata of Marfan syndrome.TABLE 1 Athletes Identiﬁed With Cardiac Disorders Associated With
Athlete Diagnosis Screening
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() ¼ negative; (þ) ¼ positive; ECG ¼ electrocardiogram; Echo ¼ echocardiogram; EP
LVEDD ¼ left ventricular end-diastolic diameter; MRI ¼ magnetic resonance imaging.ECG abnormalities were present in 22 athletes
(2.8%). Male and female athletes (3.6% vs. 1.7%;
p ¼ 0.131), and African-American and Caucasian ath-
letes (3.5% vs. 3.2%; p ¼ 0.776) had similar rates of
ECG abnormalities. The average time loss from sport
to conduct secondary testing was 6.4 days (range,
0-33 days), and there were no adverse medical events
from secondary testing or therapeutic procedures.
Five athletes (0.6%) were identiﬁed with cardiac
conditions associated with SCD, including hypertro-
phic cardiomyopathy (n ¼ 1), genetically conﬁrmed
long QT type I (n ¼ 1), and Wolff-Parkinson-White
syndrome (n ¼ 3). All athletes with potentially lethal
disorders were asymptomatic and had abnormal ECG
ﬁndings (Table 1).
This analysis demonstrates that screening by his-
tory and physical examination alone has a low
sensitivity to detect conditions associated with SCD
in college athletes and that the addition of an ECG,
when properly interpreted and with skilled cardiol-
ogy resources, improves the detection of silent/
congenital cardiac conditions associated with SCD. All
5 athletes in this cohort identiﬁed with a disorderSudden Cardiac Death
Secondary Testing Management
: IVS, 1.2 cm; posterior wall,
2 cm; LVEDD, 5.3 cm
iac MRI: apical wall thickness,
.0 cm, with late gadolinium
nhancement
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prolongation of the QTc
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tic testing: conﬁrmed KCNQ1
ene mutation for long QT
pe I
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by outside expert, declined beta-
blocker therapy, allowed to continue
rowing, no events over 4 yrs
: normal
udy: high-risk accessory
athway; status post-ablation
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abrupt loss of pre-excitation
ow-risk pathway)
Returned to sport
: normal
abrupt loss of pre-excitation
Returned to sport, interval episode of
palpitations and near-syncope led to
EP study with ablation, returned to
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¼ electrophysiological; ETT ¼ exercise treadmill test; IVS ¼ interventricular septum;
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would have been missed by only a screening history
and physical examination.
This analysis exhibits the rather vague nature and
low yield of screening questionnaires. More than one-
third of athletes reported at least 1 positive cardiac
symptom or family history response. The American
Heart Association recently expanded their primary
recommendations for screening from a 12-point to a
14-point assessment (2). However, simply asking
more questions is unlikely to improve detection of
athletes at risk when the sensitivity and speciﬁcity of
the tool itself have considerable limitations.
SCD in NCAA athletes is more frequent than initial
estimates, with an overall incidence of 1:43,000, with
male basketball players having the highest risk of SCD
at 1:7,000 athletes per year (1). Strong consideration
must be given to implementing improved models of
prevention.
Accurate interpretation of an athlete’s ECG
requires proper training and experience. The false-
positive rate in this study was only 2.2%, and
approximately 1 in 4 athletes with abnormal ECG
ﬁndings were found to have a cardiac disorder asso-
ciated with SCD. Physician expertise, cardiology,
and institutional resources vary among NCAA in-
stitutions, which will affect both the capacity and
ability to implement ECG screening. Thus, the ﬁnd-
ings of this study may not be applicable to insti-
tutions with less experience. If an ECG is included in
the cardiovascular screening of athletes, it must be
interpreted with modern standards that distinguish
physiological cardiac remodeling from ﬁndings sug-
gestive of underlying cardiac pathology and be con-
ducted with adequate cardiology oversight and
resources to assist with the secondary investigation
of ECG abnormalities.
Screening history questionnaires have a high
response rate, and their value in the detection of
athletes at risk when used as the sole screening
tool is uncertain. ECG screening increases the
ability to identify athletes with disorders associated
with SCD and thus meet the primary objective of
pre-participation screening. An integrated cardio-
vascular screening that includes an ECG should be
considered best practice for the pre-participation
evaluation of college athletes.*Jonathan A. Drezner, MD
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Should Be Stratiﬁed
According to the State of
Cardiomyocytes Within
the Ischemic RegionWe read the article by Fernández-Jiménez et al. (1)
published in the Journal with great interest. The in-
vestigators conclude that the evolution of myocardial
edema within a week after ischemia/reperfusion (I/R)
follows a bimodal pattern: T2 relaxation times and
water content reach the highest level at 2 h of reper-
fusion in the ischemia area, decrease to the lowest at
24 h, and rise to a peak again on day 7.
Myocardial edema, namely a bright signal intensity
zone on T2-weighted short tau inversion recovery
cardiac magnetic resonance, is referred to as an area
at risk that consists of irreversible and reversible
injured tissue. The cardiomyocytes located in the
irreversible region are necrotic and unsalvageable.
Irreversible region is surrounded by a reversible re-
gion encompassing cells that are integrated without
membrane disruption and can recover structure and
function after reperfusion. A severe degree of edema
will overwhelm the necrotic cells when reperfusion is
